Is the Hp 2-2 diabetic mouse model a good model to study diabetic nephropathy?

Diabetes Research and Clinical Practice

Volumn 100, Issue 3, 2013, Pages 289-297

  Nakhoul, Farid ^a   Nakhoul, Nakhoul ^a   Asleh, Rabea ^b   Miller Lotan, Rachel ^b   Levy, Andrew P ^b  

^a BAR ILAN UNIVERSITY   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Diabetic nephropathy; Haptoglobin; Mice model; Streptozotocin; Type 1 DM

Indexed keywords

ALBUMIN; COLLAGEN TYPE 4; HAPTOGLOBIN; IRON; LIPID PEROXIDE; SMOOTH MUSCLE ACTIN;

ALBUMINURIA; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE MODEL; GENOTYPE; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HP 2 2 DIABETIC MOUSE; INSULIN DEPENDENT DIABETES MELLITUS; IRON CHELATION; KIDNEY HYPERTROPHY; KIDNEY PROXIMAL TUBULE; LYSOSOME; LYSOSOME MEMBRANE; MOUSE; MOUSE STRAIN; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHENOTYPE; PODOCYTE; REVIEW; STRAIN DIFFERENCE; TRANSMISSION ELECTRON MICROSCOPY;

ALBUMINURIA; ANIMALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; GLOMERULAR FILTRATION RATE; MICE;

EID: 84878482764     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2013.02.004     Document Type: Review

References (31)

1. Zimmet P., Alberti K.G., Shaw J. Global and social implications of the diabetes epidemic. Nature 2001, 414:782-787.
2. Parving H.H., Tarnow L., Rossing P. Genetics of diabetic nephropathy. J Am Soc Nephrol 1996, 7:2509-2517.
3. Chowdhury T.A., Dyer P.H., Kumar S., Barnett A.H., Bain S.C. Genetic determinants of diabetic nephropathy. Clin Sci 1999, 96:221-230.
4. Levy A.P., Asleh R., Blum S., Levy N.S., Miller-Lotan R., Kalet-Litman S., et al. Haptoglobin: basic and clinical aspects. Antioxid Redox Signal 2010, 12(February (2)):293-304.
5. Goldenstein H., Levy N.S., Levy A.P. Haptoglobin genotype and its role in determining heme-iron mediated vascular disease. Pharmacol Res 2012, 66(July (1)):1-6.
6. Costacou T., Levy A.P. Haptoglobin genotype and its role in diabetic cardiovascular disease. J Cardiovasc Transl Res 2012, 5(August (4)):423-435.
7. Kalet-Litman S., Moreno P.R., Levy A.P. The haptoglobin 2-2 genotype is associated with increased redox active hemoglobin derived iron in the atherosclerotic plaque. Atherosclerosis 2010, 209(March (1)):28-31.
8. Fioretto P., Mauer M. Diabetic nephropathy-challenges in pathologic classification. Nat Rev Nephrol 2010, 6(September):508-510.
9. Brosius F.C., Alpers C.E., Bottinger E.P., Breyer M.D., Coffman T.M., Gurley S.B., et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol 2009, 20:2503-2512.
10. Breyer M.D., Bottinger E., Brosius F.C., Coffmanm T.M., Sharma K. Mouse models of diabetic nephropathy. J Am Soc Nephrol 2005, 16:27-45.
11. Fujita A., Yoh K., Shimohata H., Morito N., Ojima M., Yahagata K. A novel diabetes mellitus mouse model, MAFK-overexpressing hybride transgenic mice, developed severe diabetic nephropathy and improved with TCV-111 (Candesartan Cilexetil) treatment. Exp Anim 2012, 61(1):49-57.
12. Chang J.H., Paik S.Y., Mao L., Eisner W., Flannery P.J., Wang L., et al. Diabetic kidney disease in FVB/NJ Akita mice: temporal pattern of kidney injury and urinary nephrin excretion. PLoS ONE 2012, 7(April (4)):4.
13. Blum S., Milman U., Shapira C., Levy A.P. Pharmacogenomic application of the haptoglobin genotype in the prevention of diabetic cardiovascular disease. Pharmacogenomics 2008, 9(August (8)):989-991.
14. Asleh R., Levy A.P. In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease. Vasc Health Risk Manag 2005, 1(1):19-28.
15. Nakhoul F.M., Miller-Lotan R., Awad H., Asleh R., Jad K., Nakhoul N., et al. Pharmacogenomic effect of vitamin E on kidney structure and function in transgenic mice with the haptoglobin 2-2 genotype and diabetes mellitus. Am J Physiol Renal Physiol 2009, 296(April (4)):F830-F838. [Epub 2009 Jan 28].
16. Miller-Lotan R., Herskowitz Y., Kalet-Litman S., Nakhoul F., Aronson D., Zoabi R., et al. Increased renal hypertrophy in diabetic mice genetically modified at the haptoglobin locus. Diabetes Metab Res Rev 2005, 21(July-August (4)):332-337.
17. Asleh R., Nakhoul F.M., Miller-Lotan R., Awad H., Farbstein D., Levy N.S., et al. Poor lysosomal membrane integrity in proximal tubule cells of haptoglobin 2-2 genotype mice with diabetes mellitus. Free Radic Biol Med 2012, 53(4):779-786.
18. Miller-Lotan R., Miller B., Nakhoul F., Aronson D., Asaf R., Levy A.P. Retinal capillary basement membrane thickness in diabetic mice genetically modified at the haptoglobin locus. Diabetes Metab Res Rev 2007 Feb, 23(2):152-156.
19. Nakhoul F.M., Miller-Lotan R., Awaad H., Asleh R., Levy A.P. Hypothesis-haptoglobin genotype and diabetic nephropathy. Nat Clin Pract Nephrol 2007, 3(June (6)):339-344.
20. Strauss M., Levy A.P. Regulation of CD163 associated casein kinase II activity is haptoglobin genotype dependent. Mol Cell Biochem 2008, 317(October (1-2)):131-135.
21. Miller-Lotan R., Herskowitz Y., Kalet-Litman S., Nakhoul F., Aronson D., Zoabi R., et al. Increased renal hypertrophy in diabetic mice genetically modified at the haptoglobin locus. Diabetes Metab Res Rev 2005, 21(4):332-337.
22. Behzad N., Kim Y., John T., Crosson T., Mauer M. Atubular glomeruli and glomerulotubular junction abnormalities in diabetic nephropathy. J Am Soc Nephrol 2003, 14:908-917.
23. Vardi M., Blum S., Levy A.P. Haptoglobin genotype and cardiovascular outcomes in diabetes mellitus - natural history of the disease and the effect of vitamin E treatment. Meta-analysis of the medical literature. Eur J Intern Med 2012, 23(October (7)):628-632.
24. Blum S., Vardi M., Levy N.S., Miller-Lotan R., Levy A.P. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Atherosclerosis 2010, 211(July (1)):25-27.
25. Nankivell B.J., Tay Y.C., Boadle R.A., Harris D.C. Lysosomal iron accumulation in diabetic nephropathy. Ren Fail 1994, 16:367-381.
26. Purushothaman K.R., Purushothaman M., Levy A.P., Lento P.A., Evrard S., Kovacic J.C., et al. Increased expression of oxidation-specific epitopes and apoptosis are associated with haptoglobin genotype: possible implications for plaque progression in human atherosclerosis. J Am Coll Cardiol 2012, 60(July (2)):112-119.
27. Simpson M., Snell-Bergeon J.K., Kinney G.L., Lache O., Miller-Lotan R., Anbinder Y., et al. Haptoglobin genotype predicts development of coronary artery calcification in a prospective cohort of patients with type 1 diabetes. Cardiovasc Diabetol 2011, 10:99.
28. Moreno P.R., Purushothaman K.R., Purushothaman M., Muntner P., Levy N.S., Fuster V., et al. Haptoglobin genotype is a major determinant of the amount of iron in the human atherosclerotic plaque. J Am Coll Cardiol 2008, 52(September (13)):1049-1051.
29. Wang Y., Deb D.K., Zhang Z., Sun T., Liu W., Yoon D., et al. Vitamin D receptor signaling in podocytes protects against diabetic nephropathy. J Am Soc Nephrol 2012, 23:1977-1986.
30. Nakhoul F.M., Zoabi R., Kanter Y., Zoabi M., Skorecki K., Hochberg I., et al. Haptoglobin phenotype and diabetic nephropathy. Diabetologia 2001, 44(May (5)):602-604.
31. Sammour R.N., Nakhoul F.M., Levy A.P., Miller-Lotan R., Nakhoul N., Awad H.R., et al. Haptoglobin phenotype in women with preeclampsia endocrine 2010, 38(October (2)):303-308. [Epub 2010 Oct 23].